European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 2, 2003, Pages 145-148

  Kahlmeter, Gunnar ^a   Brown, Derek F J ^b   Goldstein, Fred W ^c   MacGowan, Alasdair P ^d   Mouton, Johan W ^e   Österlund, Anders ^a   Rodloff, Arne ^f   Steinbakk, Martin ^g   Urbaskova, Pavla ^h   Vatopoulos, Alkiviadis ⁱ  

^a Klinisk Mikrobiologi   (Sweden)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c SAINT JOSEPH HOSPITAL   (France)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^h NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

ⁱ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antibiotic resistance; Breakpoints; EUCAST

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFOTAXIME; CIPROFLOXACIN; GLYCOPEPTIDE; LINEZOLID; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; DATA BASE; DIFFUSION; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EUROPE; HEALTH CARE ORGANIZATION; INOCULATION; MEDICAL DECISION MAKING; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MYCOSIS; NOMENCLATURE; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; STANDARDIZATION; STREPTOCOCCUS PYOGENES; UNITED STATES; WILD TYPE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; EUROPE; MICROBIAL SENSITIVITY TESTS;

EID: 0041527129     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg312     Document Type: Article

References (17)

1. Comité de l'Antibiogramme de la Société Française de Microbiologie. (1996). Technical recommendations for in vitro susceptibility testing. Clinical Microbiology and Infection 2, Suppl. 1, S11-25. (Updates on http//:www.sfm.asso.fr)
2. Deutsches Institut für Normung. (1999). Medical Microbiology - Susceptibility Testing of Pathogens to Antimicrobial Agents. Pp. 58940-4. DIN, Berlin, Germany.
3. Commissie Richtlijnen Gevoeligheidsbepalingen. (2000). Interpretatie van gevoeligheidsonderzoek en gevoeligheidscriteria voor antibacteriële middelen in Nederland. Nederlands Tijdschrift voor Medische Microbiologie 8, 79-81.
4. Bergan, T., Bruun, J. N., Digranes, A. et al. (1997). Susceptibility testing of bacteria and fungi. Scandinavian Journal of Infectious Diseases. Supplementum 103, 1-36.
5. The Swedish Reference Group of Antibiotics. (1997). Antimicrobial susceptibility testing in Sweden. Scandinavian Journal of Infectious Diseases. Supplementum 105, 5-31. (Updates on http://www.srga.org)
6. MacGowan, A. P. & Wise, R. (2001). Establishing MIC breakpoints and interpretation of in vitro susceptibility tests. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 17-28. (Updates on http://www.bsac.org.uk)
7. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA.
8. European Committee on Antimicrobial Susceptibility Testing. (2000). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. EUCAST Definitive Document E. Def 1.2. Clinical Microbiology and Infection 6, 503-8.
9. European Committee on Antimicrobial Susceptibility Testing. (2000). Determination of antimicrobial susceptibility test breakpoints. EUCAST Definitive Document E. Def 2.1. Clinical Microbiology and Infection 6, 570-2.
10. European Committee on Antimicrobial Susceptibility Testing. (2000). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. EUCAST Definitive Document E. Def 3.1. Clinical Microbiology and Infection 6, 509-15.
11. European Committee on Antimicrobial Susceptibility Testing. (2001). Linezolid breakpoints. EUCAST Definitive Document E. Def 4.1. Clinical Microbiology and Infection 7, 283-4.
12. European Committee on Antimicrobial Susceptibility Testing. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth microdilution. EUCAST Discussion Document E. Dis 5.1. [Online.] http://www.escmid.org/sites/index_f.asp?par=2.4 (29 April 2003, date last accessed), in press.
13. Ridgway, G. L., Bébéar, C., Bébéar, C. M. et al. (2001). Antimicrobial susceptibility testing of intracellular and cell-associated pathogens. EUCAST Discussion Document E. Dis 6.1. [Online.] http://www.escmid.org/sites/index_f.asp?par=2.4 (29 April 2003, date last accessed).
14. Rodriguez-Tudela, J. L., Barchiesi, F., Bille, J. et al. Determination of minimum inhibitory concentrations by broth microdilution of fermentative yeasts. EUCAST Discussion Document E. Dis 7.1. [Online.] http://www.escmid.org/sites/index_f.asp?par=2.4 (29 April 2003, date last accessed), in press.
15. Drobniewski, F. (2002). Antimicrobial susceptibility testing of Mycobacterium tuberculosis. EUCAST Discussion Document E. Dis 8.1. [Online.] http://www.escmid.org/sites/index_f.asp?par=2.4 (29 April 2003, date last accessed).
16. Ringertz, S., Olsson-Liljequist B, Kahlmeter, G. et al. (1997). Antimicrobial susceptibility testing in Sweden II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance. Scandinavian Journal of Infectious Diseases. Supplementum 105, 8-12.
17. Mouton, J. W. (2002). Breakpoints: current practice and future perspectives. International Journal of Antimicrobial Agents 19, 323-31.